Denovo DB102-02 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1¿
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Denovo Biopharma, LLC
Start Date
July 10, 2018
End Date
January 15, 2021
Administered By
Duke Cancer Institute
Awarded By
Denovo Biopharma, LLC
Start Date
July 10, 2018
End Date
January 15, 2021